奥拉帕尼
卵巢癌
医学
肿瘤科
乳腺癌
PARP抑制剂
癌症
临床试验
PARP1
疾病
内科学
癌症研究
生物信息学
聚ADP核糖聚合酶
聚合酶
生物
基因
生物化学
作者
Cláudia Marchetti,Ludovica Imperiale,Maria Luisa Gasparri,Innocenza Palaia,Sandro Pignata,Terenzio Boni,Filippo Bellati,Pierluigi Benedetti Panici
标识
DOI:10.1517/13543784.2012.707189
摘要
Ovarian cancer is the most important cause of gynecological cancer-related mortality. Conventional treatments for advanced or recurrent disease offer limited results in terms of long-term responses and survival. Researches have recently focused on target therapies, which represent a new, promising, therapeutic approach, able to maximizing tumor kill and minimizing toxicity. The family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors is currently one of the most hopeful and investigated alternatives.Preclinical and clinical studies of Olaparib , the most investigated PARP inhibitor in ovarian cancer, are analyzed and discussed. Data were obtained by searching for all English peer-reviewed articles on Medline, on Cochrane Database and all on-going Phase I and II studies registered on National Cancer Institute Clinical Trials; also any related abstracts recently presented on Olaparib at major international congresses will be included.Bad prognosis and drug resistance usually affect ovarian cancer. Recent trends toward the knowledge of molecular-specific pathways have produced new target drugs. PARP inhibition mediated by Olaparib in BRCA1 (breast cancer 1) and BRCA2 (breast cancer 2)-mutated and in sporadic ovarian cancer represents a promising field of investigation. Further studies are needed to confirm initial exciting results.
科研通智能强力驱动
Strongly Powered by AbleSci AI